Jeffrey Lucero Riley
Independent DirectorMr. Jeffrey Lucero Riley, also known as Jeff, MBA., served as the Chief Executive Officer and Director at BlinkTBI, Inc. until November 2022. He served as the Chief Executive Officer and President of Synthetic Biologics, Inc. from February 3, 2012 to December 5, 2017. Mr. Riley served as the Managing Director of 526 Ventures. Mr. Riley served as the President of Telesso Technologies Limited (also known as Eiffel Technologies Ltd.) since October 2007. Mr. Riley served as Vice President of Finance and Corporate Development and Chief Business Officer of Amphora Discovery Corporation. He served as an Executive Vice President of Strategy and Corporate Development at Ontogen Corporation in California. Prior to joining Ontogen, Mr. Riley served as the Chief Operating Officer of AvMax, Inc., a biopharmaceutical company based in San Francisco. Mr. Riley served as the Chief Financial Officer and Vice President of Corporate Development for Nichols Institute Diagnostics. He was a Venture Partner at QIC BioVentures Fund. He was employed at GlaxoSmithKline LLC. He has experience in the biotechnology and pharmaceutical industries during which he negotiated numerous worldwide strategic corporate alliances, established joint ventures and assisted in obtaining venture financings to support product development. He sits on the advisory boards of an Australia-based venture fund (Queensland Biocapital Fund) and Ruga Corporation. Mr. Riley held senior corporate and commercial development positions with biotech companies Amphora Discovery, Ontogen Corporation and AvMax. His pharmaceutical and financial industry experience includes commercial management roles in Europe and Latin America for Nichols Institute, Pfizer Ltd. (also known as Pfizer Pharmaceuticals, Inc.), SmithKline Beecham Plc. and Citibank-Brazil. He served as the Chairman of Synthetic Biologics, Inc. from November 2011 to May 11, 2012 and as its Director from March 16, 2010 to December 5, 2017. He has been a Director of Gain Therapeutics, Inc. since May 2019. He serves as Director of Perle Bioscience, Inc. He served as a Director of Xenome Ltd. Mr. Riley holds a Bachelor of Science degree from Boise State University, completed coursework at UCSF/Berkeley in drug discovery/development and participated in a dual-degree graduate program (MBA/MIM) sponsored by Arizona State University's Thunderbird School of Global Management.
Positions
- Company NameGain Therapeutics, Inc.Stock CodeGANXPositionIndependent Director
